Skip to main content

Table 3 Baseline characteristics of in the 472 HCC patients

From: The association of liver function and quality of life of patients with liver cancer

Variable N % Mean ± SD
Clinical data
 Age < = 65 328 69 60 ± 12
 Male gender 419 89  
ECOG
 0 144 31  
 1 299 63  
 ≥ 2 29 6  
Cirrhosis (radiological) 278 59  
Tumor morphology
 Uninodular 122 26  
 Multinodular 143 30  
 Diffuse 207 44  
Extrahepatic metastasis (nodal or distant) 108 23  
Portal vein thrombosis 152 32  
Hepatitis B surface antigen + 386 82  
Hepatitis C antibody + 30 6  
α-feto protein ≥200 mg/ml 250 53  
ALBI score 472   −2.29 ± 1.33
 Grade 1 155 32.8  
 Grade 2 265 56.2  
 Grade 3 52 11.0  
MELD score 472   9.08 ± 4.05
 Grade 1 (< 10) 319 67.6  
 Grade 2 (10–14) 109 21.4  
 Grade 3 (> 14) 52 11.0  
Child-Pugh class
 A 319 67.6  
 B 130 27.5  
 C 23 4.9  
Albumin 472 100 37.4 ± 15.2
Bilirubin 472 100 32.8 ± 45.7
INR 472 100 1.15 ± 0.17
ALP 472 100 193.4 ± 155.8
ALT 472 100 77.3 ± 69.4
Albumin-to-ALP ratio 472 100 0.29 ± 0.22
ALP-to-platelet ratio 472 100 1.20 ± 1.19
Presence of ascites 122 25.8  
Hemoglobin < 10 g/dL 27 6  
White cell count > 10 × 109/L 64 14  
Platelet count < 100 × 109/L 33 7  
1st line Treatment
 Surgical treatment 54 12  
 Local ablative therapies 29 6  
 Trans-arterial therapies 116 25  
 Systemic therapies 91 19  
 Best supportive care alone 182 38  
  1. EORTC European Organization for Research and Treatment of Cancer, ECOG Eastern Cooperative Oncology Group, ALBI Albumin-bilirubin, MELD Model for End-stage Liver Disease, INR international normalized ratio, ALP alkaline phosphatases, ALT alanine transaminase